Analysts Offer Insights on Healthcare Companies: TrovaGene (NASDAQ: TROV) and Vascular Biogenics (NASDAQ: VBLT)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TrovaGene (NASDAQ: TROV) and Vascular Biogenics (NASDAQ: VBLT) with bullish sentiments.

TrovaGene (NASDAQ: TROV)

In a report released today, Bryan Brokmeier from Cantor Fitzgerald reiterated a Buy rating on TrovaGene (NASDAQ: TROV), with a price target of $8. The company’s shares opened today at $3, close to its 52-week low of $2.80.

Brokmeier commented:

“The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold).”

According to TipRanks.com, Brokmeier is a 1-star analyst with an average return of -0.7% and a 45.7% success rate. Brokmeier covers the Healthcare sector, focusing on stocks such as Rosetta Genomics Ltd, Pacific Biosciences, and Laboratory Corp.

TrovaGene has an analyst consensus of Moderate Buy.

Vascular Biogenics (NASDAQ: VBLT)

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Vascular Biogenics (NASDAQ: VBLT) yesterday and set a price target of $17. The company’s shares opened today at $5.70.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -11.7% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Vascular Biogenics has an analyst consensus of Strong Buy.